Literature DB >> 1353411

Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.

A von Deimling1, D N Louis, K von Ammon, I Petersen, O D Wiestler, B R Seizinger.   

Abstract

Previous studies have shown frequent allelic losses of chromosomes 9p, 10, 17p, and 22q in glial tumors. Other researchers have briefly reported that glial tumors may also show allelic losses of chromosome 19, suggesting a putative tumor suppressor gene locus on this chromosome (D. T. Ransom et al., Proc. Am. Assoc. Cancer Res., 32:302, 1991). To evaluate whether loss of chromosome 19 alleles is common in glial tumors of different types and grades, we performed Southern blot restriction fragment length polymorphism analysis for multiple chromosome 19 loci in 122 gliomas from 116 patients. Twenty-nine tumors had loss of constitutional heterozygosity of 19q, and four tumors had partial deletions of 19q. Allelic losses on 19q were restricted to grade III anaplastic astrocytomas (4/9) and grade IV glioblastomas (11/46), grade II oligodendrogliomas (2/5) and grade III anaplastic oligodendrogliomas (2/2), and grade II (5/8) and grade III (5/7) mixed oligoastrocytomas. These data demonstrate genetic similarities between astrocytomas, oligodendrogliomas, and mixed glial tumors and indicate the presence of a glial tumor suppressor gene on chromosome 19q.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353411

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

Review 2.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 3.  Recent advances in the treatment of oligodendrogliomas.

Authors:  Mark Agulnik; Warren P Mason
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

4.  Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes.

Authors:  Rajiv Mangla; Daniel Thomas Ginat; Shervin Kamalian; Michael T Milano; David N Korones; Kevin A Walter; Sven Ekholm
Journal:  J Neurooncol       Date:  2013-11-01       Impact factor: 4.130

5.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 6.  Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches.

Authors:  Haley J Abel; Eric J Duncavage
Journal:  Cancer Genet       Date:  2013-11-20

7.  Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas.

Authors:  C E Jones; M B Davis; J L Darling; J F Geddes; D G Thomas; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

8.  Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.

Authors:  Akira Nakamizo; Takanori Inamura; Kiyonobu Ikezaki; Koji Yoshimoto; Satoshi Inoha; Masahiro Mizoguchi; Toshiyuki Amano; Masashi Fukui
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

Review 9.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

10.  Deletions on the long arm of chromosome 17 in pilocytic astrocytoma.

Authors:  A von Deimling; D N Louis; A G Menon; K von Ammon; I Petersen; D Ellison; O D Wiestler; B R Seizinger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.